A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders

Phase 3

Recruiting

• Conditions: Neuromyelitis Optica Spectrum Disorders

• Registration Number: NCT03330418
• Lead Sponsor: RemeGen Co., Ltd.

Brief Summary

The purpose of this study is to initially observe the safety and effectivity of RC18 in Participants with Neuromyelitis Optica Spectrum Disorders.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-10-31
• Study First Submitted QC: 2017-10-31
• Study First Posted: 2017-11-06
• Study Start: 2018-01-29
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-24
• Last Update Posted: 2023-11-27
• Primary Completion: 2025-05
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 166

Inclusion Criteria

• Meet the 2015 international consensus diagnostic criteria for Neuromyelitis Optica Spectrum Disorders and astrocyte water channel aquaporin-4 (AQP4) antibody positivity.
• EDSS 0-7.5
• Clinical evidence of at least 2 relapses within the first two years of randomization and/ or 1 relapse within the first one year of randomization
• Consent to use effective contraception during the study period (women of childbearing age)
• Voluntarily signed informed consent

Exclusion Criteria

• Abnormal laboratory parameters need to be excluded, including but not limited to:
• Currently suffering from active hepatitis or serious liver disease and medical history
• Patients were treated with rituximab or other monoclonal antibodies within 6 months prior to randomization .
• Any concomitant disease other than neuromyelitis optica（NMO）/ neuromyelitis optica Spectrum disorders（NMOSD）that required treatment with lucocorticoid.
• pregnant , lactating women and men or women who have birth plans during the research;
• Have a history of allergic reaction to contrast agent for parenteral administration and human biological medicines.
• Receipt of intravenous immune globulin （ IVIG） within 28 days prior to randomization.
• Receipt of any of the following prior to randomization: Azathioprine,Cyclosporin, Methotrexate Mitoxantrone,Cyclophosphamide,Tocilizumab,Tacrolimus,Mycophenolate,and Patients discontinued more than 5 times the half-life of the drug before they could get into the group .If the patients taking leflunomide and teriflunomide,they should need to take colestyramine for elution.
• Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking shorter time ).
• The patients have severe psychiatric symptoms and are not compatible with clinical studies
• Malignant tumor patients ;
• patients experienced any of the following events within 12 weeks before screening : myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association class IV heart failure
• Patients can't accept magnetic resonance imaging inspection during the trial.
• Infection with herpes zoster or HIV virus at the screening;
• The anti-hepatitis C virus （anti-HCV） of patients show positive;
• Investigator considers candidates not appropriating for the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Time to first relapse after randomization	144 weeks

Secondary Outcome Measures

Name	Time	Method
Change from Baseline in Expanded Disability Status Scale (EDSS) Score at week 4,8,12,24,36,48,60,72,96,120,144	144 weeks	The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death) in half-point increments.
Change from Baseline in Hauser Ambulation Index at week 4,8,12,24,36,48,60,72,96,120,144	week 4,8,12,24,36,48,60,72,96,120,144

Trial Locations

Locations (1)

Beijing Hospital; 🇨🇳 Beijing, Beijing, China